Physician profile
Charles W Daniel
NPI 1932108172
$903.72
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $94.67 · 2021: $70.38 · 2022: $139 · 2023: $171 · 2024: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $271.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $188.01 | 2019-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Tris Pharma INC | $187.96 | 2019-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $76.65 | 2019-2022 | |
| Corium, LLC | $67.38 | 2022-2023 | Azstarys |
| Sanofi Pasteur INC. | $67.33 | 2021-2024 | |
| Sobi, INC | $51.81 | 2021-2023 | |
| Pfizer INC. | $46.83 | 2019-2024 | |
| Rhodes Pharmaceuticals L.P. | $44.60 | 2019 | |
| Adlon Therapeutics L.P. | $43.33 | 2019-2020 | |
| Kaleo, INC. | $31.34 | 2019-2022 | |
| Glaxosmithkline, LLC. | $22.85 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.64 | 2024 | Flumist Quadrivalent |
| Aytu Biopharma, INC. | $15.14 | 2023 | Karbinal |
| Alexion Pharmaceuticals, INC. | $15.00 | 2019 | |
| Seqirus USA INC | $13.44 | 2023 | Flucelvax Quadrivalent |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $13.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.